Associated tags: Health, Myriad Genetics, Myriad, Genetics, Medicine, Genetic testing, MYGN, SALT, Patient, Association for Molecular Pathology v. Myriad Genetics, Inc., Pharmaceutical industry, Cancer
Locations: CALIFORNIA, GEORGIA, UTAH, TN, MS, LOYOLA, BALTIMORE, SALT LAKE CITY, UT, US, SALT, RHODE ISLAND, MASSACHUSETTS, KENTUCKY
Retrieved on:
Wednesday, April 17, 2024
When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present. Nearly eight in 10 respondents (78%) said poor mental health prevented them from “having fun/enjoying myself” in the past year -- a number that jumps to 82% for those diagnosed with anxiety and/or depression.
Key Points:
- SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health.
- Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime because of poor mental health – and 12% said they’ve lost decades.
- When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present.
- “I had to call off my wedding to focus on my mental health,” said Courtney Nugent, a GeneSight patient based in Massachusetts.
Patient,
DiGeorge syndrome,
American College,
MYGN,
Pregnancy,
Test management,
Myriad Genetics,
Ventricular septal defect,
FACMG,
MD,
Doctor of Philosophy,
Genetic testing,
Medical genetics,
Genetics,
DNA,
SNP,
PPV,
Genomics,
Medicine,
FACOG,
Dietary supplement “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
Key Points:
- “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
- This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
- 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
- The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.
(NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .
Key Points:
- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .
- “We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics.
- We expect to share additional study results later this year.”
The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:
39% relative reduction in psychiatric-related hospitalizations.
- Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions.
MYGN,
Diagnosis,
Genetic testing,
Patent,
Combinatorics,
Genetics,
Patient,
Neoplasm,
Research,
DNA,
Myriad Genetics,
Doctor of Philosophy,
Oncology,
Medicine,
University,
MD Anderson Cancer Center,
MRD,
Intellectual property,
FDA,
Estate (law),
Pharmaceutical industry U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
Key Points:
- U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
- This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
- Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
- “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.
Retrieved on:
Wednesday, March 20, 2024
MYGN,
PCR,
Arm,
Genetic testing,
Patent,
Risk,
Genetics,
DNA,
Snap,
Myriad Genetics,
Doctor of Philosophy,
Medicine,
Male,
Pharmaceutical industry 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
Key Points:
- 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
- Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes.
- “We view this patent grant as recognition of our innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device,” stated Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.
- “This patent grant promotes SneakPeek Snap exclusivity in the US market through at least 2040 and provides an opportunity for licensing agreements with leading push-button blood collection device suppliers, positioning us as a strategic partner.”
Retrieved on:
Tuesday, February 27, 2024
Acquisition,
Breast cancer,
Neoplasm,
Cancer,
SSO,
Forecasting,
MD,
ASCO,
Growth,
GM,
American College of Neuropsychopharmacology,
Surgical oncology,
Myriad Genetics,
Society,
Capital expenditure,
GAAP,
Genetics,
American College,
Health,
Patient,
Public expenditure,
Women's health,
MCRR,
IPG,
Video game SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and full-year ended December 31, 2023 and provided its outlook on business performance for its first quarter and full-year 2024.
Key Points:
- GAAP operating expenses in the fourth quarter of 2023 were $166.4 million, decreasing $9.7 million year-over-year.
- Adjusted operating expenses in the fourth quarter of 2023 decreased $8.6 million year-over-year to $130.0 million, reflecting incremental cost control measures during the fourth quarter 2023.
- GAAP operating loss in the fourth quarter of 2023 was $31.4 million, improving $20.8 million year-over-year; adjusted operating income in the fourth quarter of 2023 was $5.7 million, improving $19.6 million year-over-year from adjusted operating loss of $13.9 million in the fourth quarter of 2022.
- Fourth quarter 2023 GAAP cash flow from operations was $(55) million; adjusted cash flow from operations in the fourth quarter of 2023 was $14 million, an increase of $10 million year-over-year.
Retrieved on:
Tuesday, February 27, 2024
VEGA,
ALTAIR,
Division,
Recurrence,
Doctor of Philosophy,
MYGN,
Cancer,
Myriad Genetics,
WGS,
Neoplasm,
Medicine,
Genetic testing,
Patient,
MRD,
Genetics,
Head,
Colorectal cancer,
Research,
DNA Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
Key Points:
- Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
- The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.
- “First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden.
- “We’ve designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care.”
Retrieved on:
Wednesday, February 21, 2024
SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.
Key Points:
- SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m.
- The company’s quarterly earnings will be released the same day after the market closes.
- During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023.
- The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.
Retrieved on:
Thursday, February 15, 2024
Cancer,
OBGYN,
Medicine,
Education,
MYGN,
FACMG,
Dillard University,
Boston Market,
Risk,
Health,
Myriad Genetics,
FACOG,
Genetics,
Risk assessment,
Associate,
Genetic testing,
Biology,
Tufts Medical Center,
Nursing SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
Key Points:
- SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
- Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
- “We’re thrilled to welcome Dallas to the Myriad team.
- She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.
Retrieved on:
Thursday, February 1, 2024
Cancer,
Neoplasm,
Genetics,
RNA,
LCD,
DNA,
Patient,
Intermountain Health,
Genetic testing,
MYGN,
Medicine,
Acquisition,
IPG,
Medicare,
Medical imaging SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
Key Points:
- SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah.
- Myriad’s Precise Tumor Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a patient’s tumor DNA to discover and target important variants within tumors.
- Myriad will operate TheraMap: Solid Tumor solely as Precise Tumor moving forward.
- Precise Liquid, which is expected to launch later this year, will provide convenient comprehensive genomic profiling results from a blood draw.
